DIAN-TU Overview and Next Steps, Part 2

Description: An update on the results of clinical trials being conducted by the DIAN Trials Unit, using the drugs gantenerumab and solanezumab, along with an update on recruitment of DIAN trial participants in Latin America
Runtime: 00:21:24

Speaker: Randall Bateman, MD
Speaker title: DIAN Trials Unit Director
Speaker organization: Washington University in St. Louis

Speaker: Jorge J. Llibre Guerra, MD, MSc
Speaker title: DIAN Trials Unit Research Fellow
Speaker organization: Washington University in St. Louis

Event: 2020 Virtual DIAD Family Conference
Year: 2020

Search tags: clinical trials, risk and safety, drug dosing, amyloid plaques, biomarkers, primary prevention, secondary prevention, open-label extension, gantenerumab, solanezumab, Cognitive Run-In, DIAN-TU-001 Trial, DIAN-TU-002 Trial, CSF ptau phosphorylation, public-private partnership, DIAN-TU NexGen Trials, tau tangles, drug targets, amyloid plaques, Latin America, research participation, PSEN1, PSEN2, APP, genetic testing, risk factors, environmental factors, behavioral factors, protective factors